Aurora Cannabis Inc. (ACB) Stock Price & Analysis
Aurora Cannabis Inc. (ACB) is trading at USD 3.9, down 1.89% today, as of October 23, 2026 at 16:59 UTC (US market open; quotes may be delayed), according to Nexqual market data.
ACB last closed at USD 3.9; today's session has ranged USD 3.87–3.96 on volume of 400,546 shares. Market capitalization is —, with a 52-week range of USD 2.56–6.36 (NCM). Source: Nexqual, retrieved October 23, 2026 at 17:02 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ACB.md
Key facts (ACB)
- Total return with dividends: 1Y -23.8% vs S&P 500 +14.6%; 5Y -94.1% vs S&P 500 +77.3%.
- Next earnings: 2026-11-04, EPS estimate USD -0.05, revenue estimate $73.4M.
Total return (dividends reinvested) (ACB)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -23.8% | -94.1% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | -23.8% | -43.3% |
| Volatility (annualized) | 55.4% | 81.0% |
| Max drawdown | -53.7% (Dec 2025→Jul 2026) | -96.9% (Nov 2021→Jul 2026) |
ACB analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.05 | $-0.15 | -63.8% | $73.4M | 3 |
| Next quarter (ends Dec 2026) | $-0.01 | $-0.09 | -92.4% | $76.5M | 3 |
| Current fiscal year (ends Mar 2027) | $-0.11 | $-0.34 | -68.1% | $295.0M | 5 |
| Next fiscal year (ends Mar 2028) | $0.11 | $0.02 | +511.1% | $322.7M | 4 |
Key Statistics (as of October 23, 2026 at 17:02 UTC)
| Price | USD 3.9 |
|---|---|
| Change | ▼ 1.89% (down) |
| Previous Close | USD 3.9 |
| Open | USD 3.9 |
| Day Range | USD 3.87 – 3.96 |
| 52-Week Range | USD 2.56 – 6.36 |
| Volume | 400,546 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (ACB)
Nexqual's technical model rates ACB "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of October 23, 2026 at 17:02 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.5 (neutral) |
| vs SMA50 | Below (USD 4.01) |
| MACD | -0 (negative) |
Earnings (ACB)
| Next Earnings Date | 2026-11-04 |
|---|---|
| Revenue Estimate | $73.40M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.07 vs est -0.21 ▲ beat |
| 2026-03-31 | USD -0.99 vs est -0.14 ▼ miss |
| 2025-12-31 | USD 0.03 vs est -0.09 ▲ beat |
| 2025-09-30 | USD -0.91 vs est -0.1 ▼ miss |
Source: Nexqual, October 23, 2026 at 17:02 UTC.
Financials & Fundamentals (ACB)
| Total Revenue | $314.07M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -8.80% |
| Gross Margin | +44.18% |
| Operating Margin | -12.92% |
| Profit Margin | -38.25% |
| ROE | -9.40% |
| Debt / Equity | 0.04 |
| Current Ratio | 5.36 |
| Total Cash | $100.03M |
| Total Debt | $22.68M |
Source: Nexqual, October 23, 2026 at 17:02 UTC.
Ownership (ACB)
| Insider Ownership | +1.21% |
|---|---|
| Institutional Ownership | +9.36% |
| Shares Outstanding | 63.31M |
| Float | 64.47M |
Source: Nexqual, October 23, 2026 at 17:02 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | USD 6.33 | ▼ 2.47% |
| SUPN | Supernus Pharmaceuticals, Inc. | USD 40.39 | ▼ 3.99% |
| HCM | HUTCHMED (China) Limited | USD 14.4 | ▲ 0.84% |
| LQDA | Liquidia Corporation | USD 41.35 | ▲ 4.18% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.7 | ▼ 3.05% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 34.3 | ▼ 2.92% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 17:02 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt